Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2002

View Archived Issues

Orally available thrombin inhibitor designed at LG Chem

Fujisawa reveals new series of potent human Y5 receptor antagonists

U.S. researchers successfully design soft cannabinoid analogues with potential in glaucoma Rx

Extended pharmacokinetics, pharmacodynamics confirmed for Albuferon in primates

PPARalpha may play an important role in angiotensin II-induced hypertension

Preclinical data for M-100240 reported at ASH meeting

Tadalafil: a new treatment option for men with erectile dysfunction

New data on rosiglitazone reported at the ASH meeting

Dose-dependent efficacy of the renin inhibitor aliskiren confirmed in hypertensive patients

Potential efficacy of adenosine analogue in atherosclerotic and inflammatory processes

Phase III data on Cidecin in complicated skin and soft tissue infections

Wyeth announces corrections to sirolimus prescribing information

COMT inhibitors useful for Rx of Parkinson's disease described in recent patent

(S)-Amlodipine enters phase II for treatment of hypertension

NCX-4016 inhibits vascular inflammation and platelet activation in phase I/IIa study

Biosearch reacquires North American rights to topical ramoplanin

Isotechnika and Roche focus ISAtx-247 development on transplantation

Enrollment completed in phase I trial of DAC:TI in hemodialysis patients with AV shunts

Genmab and ACE BioSciences to develop antibody therapeutics for infectious diseases

FDA advisory committee hands down positive opinion on acamprosate NDA

Bryostatin 1 gains E.U. orphan drug designation in esophageal cancer

Glycine transporter inhibitors and uses thereof claimed by Gliatech

Merck KGaA patents nicotinic acetylcholine receptor agonists

Benzamidine derivatives from Genentech inhibit serine proteases involved in thrombosis

Recent patent covers new agents for melatonergic system disorders

Antagonists at integrin receptors described for bone disorders, etc.

Merck presents new series of thrombin inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...